AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Guardian Capital Advisors LP

Guardian Capital Advisors LP lowered its position in shares of AstraZeneca PLC (NASDAQ:AZNFree Report) by 4.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 56,228 shares of the company’s stock after selling 2,355 shares during the period. Guardian Capital Advisors LP’s holdings in AstraZeneca were worth $3,892,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in AZN. Anchor Investment Management LLC purchased a new position in AstraZeneca in the fourth quarter worth $26,000. Compagnie Lombard Odier SCmA purchased a new position in shares of AstraZeneca in the 4th quarter valued at about $27,000. Nemes Rush Group LLC boosted its holdings in AstraZeneca by 375.6% during the third quarter. Nemes Rush Group LLC now owns 428 shares of the company’s stock worth $29,000 after buying an additional 338 shares in the last quarter. Northwest Financial Advisors acquired a new position in AstraZeneca during the fourth quarter worth about $34,000. Finally, LWM Advisory Services LLC purchased a new position in AstraZeneca in the third quarter valued at about $35,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of AZN traded down $0.39 during trading hours on Tuesday, reaching $77.04. 4,115,924 shares of the company traded hands, compared to its average volume of 6,223,467. The stock has a market capitalization of $238.86 billion, a PE ratio of 37.76, a price-to-earnings-growth ratio of 1.40 and a beta of 0.47. The stock has a fifty day simple moving average of $70.03 and a 200 day simple moving average of $67.00. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $77.93. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Morgan Stanley started coverage on AstraZeneca in a research note on Tuesday, January 23rd. They set an “overweight” rating for the company. Finally, BMO Capital Markets raised their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus price target of $81.00.

Read Our Latest Analysis on AZN

About AstraZeneca

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Stories

Want to see what other hedge funds are holding AZN? Visit to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.